Abstract

Reshma Kodumuru

The pharmaceutical industry is moving rapidly to ward digital manufacturing, with Artificial Intelligence (AI) and the Internet of Things (IoT) becoming central to predictive monitoring, process optimization, and personalized therapies. In our recent review, we ex amined the technological frameworks enabling this transformation. This commentary builds on that dis cussion and emphasizes three priority areas: (i) ro bust data governance as the foundation of reliable digital manufacturing, (ii) regulatory approaches that evolve alongside adaptive technologies, and (iii) the need to reframe workforce roles in the era of digital oversight. By highlighting these dimensions, I argue that the long-term success of AI–IoT integration will be defined not only by efficiency gains but also by the sector’s ability to sustain trust, transparency, and patient safety